Centene CORP Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NYSE
Lauren M Tyler, a Director of Centene Corp, received 482 shares of common stock on September 30, 2026.
NYSE
Kenneth Tanji, a Director of Centene Corp, received 603 shares of common stock on September 30, 2026.
NYSE
Theodore R. Samuels Ii, a Director of Centene Corp, received 583 shares of common stock on September 30, 2026.
NYSE
Frederick H Eppinger, a Director of Centene Corp, received 864 shares of common stock on September 30, 2026.
NYSE
Christopher J Coughlin, a Director of Centene Corp, received 583 shares of common stock on September 30, 2026.
NYSE
Theodore J Pienkos, Corporate Controller & CAO of Centene Corp, reported a transaction in 1,092 shares of common stock on September 15, 2026.
NYSE
Christopher Koster, Secretary & General Counsel of Centene Corp, sold 56,500 shares of common stock on August 26, 2026 for $66.90 per share.
NYSE
Christopher Koster, Secretary & General Counsel of Centene Corp, sold 47,603 shares of common stock on August 18, 2026 for $65.36 per share.
NYSE
Paul J Diaz, a Director of Centene Corp, received 2,771 shares of common stock on July 28, 2026.
NYSE
Lauren M Tyler, a Director of Centene Corp, received 3,155 shares of common stock on July 17, 2026.
NYSE
Centene Corp. director Lauren M. Tyler acquired 61 shares of common stock on June 30, 2026, through a transaction valued at $0.
NYSE
Centene Corp. reports a director, Kenneth Tanji, acquired 581 shares of common stock on June 30, 2026.
NYSE
Centene Corp. Director Theodore R. Samuels II reported the acquisition of 465 shares of common stock on June 30, 2026.
NYSE
Centene Corp director Frederick H. Eppinger acquired 833 shares of common stock on June 30, 2026, increasing his direct beneficial ownership.
NYSE
Centene Corp. director Christopher J. Coughlin reported the acquisition of 562 shares of common stock on June 30, 2026.
NYSE
Susan Raye Smith, Chief Operating Officer of Centene Corp, reported a transaction involving common stock on June 15, 2026.
NYSE
Centene Corporation Director Kenneth A. Burdick reported the sale of 80,000 shares of common stock at an average price of $64.55.
NYSE
Michael A. Carson, Group President of Medicare & Specialty at Centene Corp, reported a transaction involving phantom stock units on May 29, 2026.
NYSE
Michael A. Carson, Group President of Medicare & Specialty at Centene Corp, reported transactions involving common stock and phantom stock.
NYSE
Centene Corporation Director Kenneth Tanji was granted 3,992 restricted stock units as part of an equity compensation award.
NYSE
Centene Corporation Director Theodore R. Samuels II was granted 3,992 restricted stock units as part of an equity award.
NYSE
Centene Corporation director Monte E. Ford acquired 3,992 restricted stock units as part of an equity compensation award.
NYSE
Centene Corporation Director Frederick H. Eppinger was granted 6,654 restricted stock units as part of an equity award.
NYSE
Centene Corporation Director James Dallas acquired 3,992 restricted stock units as part of an equity compensation award.
NYSE
Centene Corporation Director Christopher J. Coughlin was granted 3,992 restricted stock units as part of his compensation.
NYSE
Centene Corporation Director Kenneth A. Burdick acquired 3,992 shares of common stock via a restricted stock unit grant.
NYSE
Centene Corporation Director Jessica Blume acquired 3,992 restricted stock units as part of an annual equity award.
NYSE
Centene Corporation Chief People Officer Tanya McNally reported the withholding of 964 shares to cover tax obligations related to restricted stock unit vesting.
NYSE
Centene Corp Director Kenneth Tanji acquired 1,179 shares of common stock on March 31, 2026, under a pre-arranged trading plan.
NYSE
Centene Corp. Director Theodore R. Samuels II acquired 943 shares of common stock on March 31, 2026, increasing his direct beneficial ownership.